Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Frédéric Viret, Christelle Levy, Aurélien Robert, Julien Grenier, Laura Mansi, Jean-Philippe Spano, Anne Patsouris, Olfa Derbel, Christelle Jouannaud, Jean Marc Ferrero, Jean Sébastien Frenel, Yann Molin, Louis Doublet, Pierre-Etienne Heudel, Jean-Yves Pierga, Gwenaële Garin, David Pérol, Thomas Bachelot

Open source

DOI: 10.1016/j.breast.2025.104648
Published: 2026-02
Container: The Breast
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2025.104648,
  title = {Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03},
  author = {Olivier Trédan and Delphine Loirat and Sylvie Chabaud and Philippe Toussaint and Thierry Petit and Frédéric Viret and Christelle Levy and Aurélien Robert and Julien Grenier and Laura Mansi and Jean-Philippe Spano and Anne Patsouris and Olfa Derbel and Christelle Jouannaud and Jean Marc Ferrero and Jean Sébastien Frenel and Yann Molin and Louis Doublet and Pierre-Etienne Heudel and Jean-Yves Pierga and Gwenaële Garin and David Pérol and Thomas Bachelot},
  year = {2026},
  journal = {The Breast},
  doi = {10.1016/j.breast.2025.104648},
  url = {https://doi.org/10.1016/j.breast.2025.104648}
}

RIS

TY  - JOUR
TI  - Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03
AU  - Olivier Trédan
AU  - Delphine Loirat
AU  - Sylvie Chabaud
AU  - Philippe Toussaint
AU  - Thierry Petit
AU  - Frédéric Viret
AU  - Christelle Levy
AU  - Aurélien Robert
AU  - Julien Grenier
AU  - Laura Mansi
AU  - Jean-Philippe Spano
AU  - Anne Patsouris
AU  - Olfa Derbel
AU  - Christelle Jouannaud
AU  - Jean Marc Ferrero
AU  - Jean Sébastien Frenel
AU  - Yann Molin
AU  - Louis Doublet
AU  - Pierre-Etienne Heudel
AU  - Jean-Yves Pierga
AU  - Gwenaële Garin
AU  - David Pérol
AU  - Thomas Bachelot
PY  - 2026
JO  - The Breast
DO  - 10.1016/j.breast.2025.104648
UR  - https://doi.org/10.1016/j.breast.2025.104648
ER  -

APA

Trédan, O., Loirat, D., Chabaud, S., Toussaint, P., Petit, T., Viret, F., Levy, C., Robert, A., Grenier, J., Mansi, L., Spano, J., Patsouris, A., Derbel, O., Jouannaud, C., Ferrero, J. M., Frenel, J. S., Molin, Y., Doublet, L., Heudel, P., Pierga, J., Garin, G., Pérol, D., & Bachelot, T. (2026). Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03. The Breast. https://doi.org/10.1016/j.breast.2025.104648

Source records

crossref · retrieved 2026-09-26T09:51:40.242Z